Results 11 to 20 of about 5,080 (193)

Lecanemab for mild Alzheimer disease – is there a way forward?

Drugs in Context
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab ...
Rajesh R Tampi
doaj   +2 more sources

Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease [PDF]

Frontiers in Public Health
IntroductionLecanemab is the second anti-amyloid-β monoclonal antibody to receive FDA approval for the treatment of early Alzheimer’s disease (AD), following aducanumab.
Xiangxiang Jiang, Gang Lv, Morgan E. Mendes, Jun Wu, Jing Yuan, Z. Kevin Lu   +5 more
doaj   +2 more sources

Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease

Journal of Alzheimer's Disease Reports
Lecanemab has demonstrated amyloid reduction and slowed clinical decline in early Alzheimer's disease trials. Herein, we report retrospective case series results on lecanemab treatment in our clinic. Overall, 61 individuals were included.
Alyanna Ferrer, Justin Moon
doaj   +2 more sources

[¹²⁵I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [¹⁸F]Flotaza and [¹²⁵I]IBETA in Postmortem Human Alzheimer’s Disease [PDF]

Neurology International
Therapeutic antibodies for reducing Aβ plaque load in Alzheimer’s disease (AD) is currently making rapid progress. The diagnostic imaging of Aβ plaque load in AD has been underway and is now used in clinical studies.
Christopher Liang, Cayz G. Paclibar, Noresa L. Gonzaga, Stephanie A. Sison, Harman S. Bath, Agnes P. Biju, Jogeshwar Mukherjee   +6 more
doaj   +2 more sources

Lecanemab appropriate use recommendations for clinical practice in the UK. [PDF]

J Neurol Neurosurg Psychiatry
Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) heterozygotes or non ...
Mummery CJ, Rasmussen J, Blackburn D, Coulthard E, Davies RR, Dorsey R, Fox NC, Hosseini AA, Ivenso C, Jones M, Kennelly SP, Kipps C, Lashley D, Mackay G, Negi R, Nilforooshan R, Passmore PA, Perry R, Raymont V, Rowe JB, Russ TC, Taylor JP, Burns A.   +22 more
europepmc   +11 more sources

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Alzheimer’s Research & Therapy
Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment of early AD ...
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer   +13 more
doaj   +2 more sources

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

Neurology and Therapy, 2023
Introduction Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with memory, cognitive, and behavioral deficits, and brings significant economic burden on caregivers and healthcare systems.
Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kang Kang, Quanwu Zhang   +6 more
doaj   +2 more sources

Shunt surgery and lecanemab therapy in patients with idiopathic normal pressure hydrocephalus and alzheimer’s disease: a report of two cases

Acta Neurochirurgica
Idiopathic normal pressure hydrocephalus (iNPH) is a condition in the elderly commonly treated with ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery.
Koichi Miyazaki, Hiroya Morita, Kazunari Ishii   +2 more
doaj   +2 more sources

Lecanemab for Alzheimer’s disease [PDF]

BMJ, 2022
New trial reports little to celebrate for patients and ...
Walsh, Sebastian, Merrick, Richard, Richard, Edo, Nurock, Shirley, Brayne, Carol   +4 more
openaire   +2 more sources

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Alzheimer’s Research & Therapy, 2022
Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of this analysis is
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman   +9 more
doaj   +1 more source